Magnetic Resonance Imaging in the Diagnosis of Pulmonary Hypertension

The aim of the present study is to identify changes in the cardiovascular system in patients with pulmonary hypertension (PH) by magnetic resonance imaging (MRI). MRI is accepted as golden standard method for the evaluation of left and right ventricular morphology and function.

All patients who showed elevated pulmonary pressure in the right heart catheter investigation are assigned to MRI. Parameters derived from MRI are included in the clinical and therapeutic decisions. Well established as well as new MRI parameters are evaluated and compared to the results of right heart catheter. Further age-matched controls without known cardiac or pulmonary disease are investigated by native MRI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Hypertension Cardiovascular Diseases Hypertension Hypertension, Pulmonary Late Enhancement Patterns Lung Diseases MR Phase Contrast Velocity Imaging Respiratory Tract Diseases Vascular Diseases Ventricular Function

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical Unitersity Graz, University Clinic of Internal Medicine, Department of Pulmonology

Graz, Stmk., 8036, Austria

About this study

Patients with suspected, latent and manifest PH and controls are investigated by MRI according to the following protocol in breathhold or free breathing (depending on the patients' breath-hold abilities). In case of elevated Creatinin values, no contrast agent is applied.

Planning of cardiac views: Planning of 2-chamber view, short axes view and 4-chamber view.
Morphological overview: Transversal and coronal Haste images
Left and right heart functional and valve evaluation: Cine 2-chamber imaging, Multi-slice cine 4-chamber imaging, Cine Left and Right ventricular outflow tract imaging and Multi-slice cine short axes imaging covering the left and right ventricle for evaluation of EDV, ESV, SV, EF, CO and muscle mass.
Phase Contrast Imaging: Flow measurements in the aorta, the pulmonary artery and the heart.
Perfusion measurement.
Late enhancement measurement: Multi-slice short axes view, multi-slice 2-chamber view and multi-slice 4-chamber view.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Controls without history of cardiac or pulmonary diseases
Patients with suspected PH
Patients with latent PH
Patients with manifest PH

Exclusion criteria

MRI exclusion criteria

Treatment and study plan

Primary outcomes

right ventricular function

Time frame: at the MRI investigation

right ventricular end-diastolic volume (EDV), right ventricular end-systolic volume (ESV), right ventricular stroke volume (SV), right ventricular ejection fraction (EF), right ventricular cardiac output (CO), right ventricular muscle mass (RVMM)

Sponsors and collaborators

Lead sponsor

Medical University of Graz

Other

Registry information

Important dates

Study start: 2006
Primary completion: 2013
Study completion: 2013
First posted: Dec 18, 2007
Registry last updated: May 28, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed